Published in:
01-09-2014 | Correspondence
Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants
Authors:
Sonja Hutter, Rosario M. Piro, David E. Reuss, Volker Hovestadt, Felix Sahm, Said Farschtschi, Hildegard Kehrer-Sawatzki, Stephan Wolf, Peter Lichter, Andreas von Deimling, Martin U. Schuhmann, Stefan M. Pfister, David T. W. Jones, Victor F. Mautner
Published in:
Acta Neuropathologica
|
Issue 3/2014
Login to get access
Excerpt
Schwannomatosis (MIM #162091) is characterized by the development of multiple schwannomas without vestibular nerve involvement (which is a characteristic of neurofibromatosis type 2—NF2—MIM #101000). About 10 % of patients have a family history of the disease, with the remaining 90 % presumed to be sporadic [
7]. Germline mutations of
NF2 are not observed [
8], although schwannomas frequently harbor somatic
NF2 mutations and often display chromosome 22 loss [
6]. Rare cases with somatic mosaicism for
NF2 alterations have also been described [
5]. Germline mutations in
SMARCB1 (
INI1), located proximal to
NF2 on chromosome 22, are found in ~30–60 % of familial and ~10 % of sporadic schwannomatosis patients [
4,
10,
12]. Recently, another schwannomatosis-predisposing gene within the 22q candidate region has been identified. Piotrowski et al. [
9] reported germline loss-of-function mutations in
LZTR1 in 80 % of familial and sporadic schwannomatosis cases with combined chr22 loss and somatic
NF2 mutation (MIM #615670). LZTR1 functions as an adaptor of the cullin 3-containing E3 ubiquitin ligase complex and has recently been implicated in glioblastoma multiforme development [
3], indicating a broader role in tumorigenesis. We therefore sought to further explore the prevalence of
LZTR1 mutations in a cohort of 23 sporadic schwannomatosis patients. …